Although high levels of IRF4 expression (and constitutive NF-κB activation) have been reported specifically for the activated B-cell subtype of DLBCL, our results suggest that common variations in IRF4 may also influence risk for CLL/SLL and MZ, in addition to DLBCL. Here, NFKB1 is linked to diffuse large B-cell lymphoma.